Breaking News

Adidas to Start EU1.5B Shareholder Return Program
Tweet TWEET

Baxter and Coherus Biosciences Announce Collaboration to Develop and Commercialize Biosimilars

  Baxter and Coherus Biosciences Announce Collaboration to Develop and
  Commercialize Biosimilars

Business Wire

DEERFIELD, Ill. & REDWOOD CITY, Calif. -- September 3, 2013

Baxter International Inc. (NYSE:BAX) and Coherus Biosciences, Inc. today
announced that they have entered into an exclusive collaboration to develop
and commercialize a biosimilar to etanercept for Europe, Canada, Brazil and
certain other markets. Additionally, the agreement allows for the expansion of
the collaboration to include another product. Biosimilars are intended to be
used in place of existing, branded biologics to treat a range of chronic and
often life-threatening diseases and have the potential to reduce costs and
expand patient access.

Under the agreement, Baxter will make an upfront payment of $30 million.
Coherus will conduct development and Baxter will make payments of up to $216
million contingent upon the achievement of development and regulatory events.
The agreement also allows for development and commercialization of an
alternative biosimilar to etanercept, pending the outcome of clinical data.

''The collaboration allows us to partner with a company that brings
demonstrated capabilities with potential to support accelerated entry into the
biosimilar market for Baxter. This collaboration and Baxter’s ongoing
relationship with Momenta expand Baxter’s pipeline, which now includes several
biosimilars in the areas of immunology and oncology,'' said Ludwig Hantson,
Ph.D., president of Baxter’s BioScience business. ''As an established
biologics leader, we’re looking forward to entering the market with biosimilar
treatments that will broaden patient access to care.''

''We are pleased to be partnering with Baxter, a premier healthcare company
that shares our strategic commitment to biosimilars,'' said Denny Lanfear,
chief executive officer of Coherus. ''This agreement further validates our
unique business model and capability to globally develop products from
conception through approval.''

About Baxter International Inc.

Baxter International Inc., through its subsidiaries, develops, manufactures
and markets products that save and sustain the lives of people with
hemophilia, immune disorders, cancer, infectious diseases, kidney disease,
trauma and other chronic and acute medical conditions. As a global,
diversified healthcare company, Baxter applies a unique combination of
expertise in medical devices, pharmaceuticals and biotechnology to create
products that advance patient care worldwide.

About Coherus Biosciences

Coherus Biosciences is a clinical stage, pure-play biosimilar company
headquartered in the San Francisco Bay Area. The company was founded by a
group of biotech pioneers brought together by the shared vision of using their
expertise and knowledge to increase global patient access to high quality,
life changing biologic medications. From conceptualization to
commercialization, Coherus’ unique business model leverages a strategic
consortium of key service providers aligned through ownership and shared
incentives. Coherus’ global partnerships include top-tier Biopharma in Europe,
Asia, and Latin America pursuing the integrated development and
commercialization of products representing over $35 billion in current sales.
For additional information, please visit www.coherus.com.

This release includes forward-looking statements concerning a development and
commercialization agreement between Baxter International Inc. and Coherus
Biosciences, Inc., including expectations with regard to future milestone
payments. The statements are based on assumptions about many important
factors, including the following, which could cause actual results to differ
materially from those in the forward-looking statements: satisfaction of
regulatory and other requirements; actions of regulatory bodies and other
governmental authorities; clinical trial results; changes in laws and
regulations; product quality or patient safety issues; and other risks
identified in Baxter's most recent filings on Form 10-K and other SEC filings.
Baxter does not undertake to update its forward-looking statements.

Contact:

Baxter International Inc.
Media Contacts
Brian Kyhos or Deborah Spak, 224-948-5353
media@baxter.com
Investor Contact
Mary Kay Ladone, 224-948-3371
or
Coherus Biosciences
George Montgomery, 650-649-3567
Chief Financial Officer
gmontgomery@coherus.com
 
Press spacebar to pause and continue. Press esc to stop.